Research into GcMAF therapy has shown promising results for prostate cancer patients. The treatment history of some patients prior to therapy can be reviewed here.
PSA testing has long been used to diagnose and monitor prostate cancer. However, during GcMAF therapy, studies observed that serum Nagalase levels decreased in tumor-bearing prostate patients, while PSA levels often remained unchanged.
This is an important finding. Nagalase appears to be a more precise biomarker for tracking tumor activity and therapeutic response than PSA alone. By monitoring Nagalase, doctors and patients can assess tumor regression rates, evaluate treatment effectiveness, and even estimate tumor differentiation.
The discovery of cancer cell-specific Nagalase as a reliable monitoring tool has significantly increased the clinical importance of GcMAF therapy. It offers new hope for better tracking of cancer progression and improved patient outcomes.
Please share this post to raise awareness.
Join our informative GcMAF group for more insights: https://www.facebook.com/groups/2053703715028393/
Don't know where to source GcMAF: https://dubaibioremedix.com/shop/
